Mycobacterium tuberculosis pyrazinamide targets (PZA/POA targets)

Pyrazinamide (PZA) is a critical first-line antibiotic used in the treatment of tuberculosis, specifically valued for its unique ability to eradicate non-replicating 'persister' Mycobacterium tuberculosis bacilli that reside in acidic environments [3, 5]. It functions as a prodrug, requiring activation by the bacterial enzyme pyrazinamidase (PncA) into the bioactive form, pyrazinoic acid (POA) [1, 6]. POA is a pleiotropic agent that disrupts multiple essential bacterial pathways, including protein trans-translation via RpsA, coenzyme A biosynthesis via PanD, and the maintenance of membrane potential and pH homeostasis [4, 17]. By targeting these diverse cellular processes, PZA significantly shortens the required duration of tuberculosis therapy from nine months to six months [15, 22]. Resistance to the drug is most commonly associated with mutations in the pncA gene, which prevent prodrug activation, though mutations in the target proteins RpsA and PanD also contribute to clinical resistance [3, 19]. In human patients, the use of PZA requires monitoring for potential side effects such as liver toxicity and hyperuricemia, the latter of which can precipitate gouty arthritis [6, 10].

Other names

Ribosomal protein S1 (RpsA)Aspartate decarboxylase (PanD)Fatty acid synthase I (FAS-I)Caseinolytic protease C1 (ClpC1)Guanosine pentaphosphate synthetase (GpsI)Mycobacterial membrane potentialTrans-translation machinery

Pyrazinamide is a prodrug that is converted into its active form, pyrazinoic acid (POA), by the bacterial enzyme pyrazinamidase (PncA) [1, 3]. POA exerts its antibacterial effects through a multi-targeted mechanism: it inhibits the trans-translation process by binding to ribosomal protein S1 (RpsA) [2, 15], disrupts coenzyme A (CoA) biosynthesis by binding to aspartate decarboxylase (PanD) and triggering its degradation via the ClpC1-ClpP protease complex [17, 22], and acts as a protonophore to dissipate the bacterial membrane potential and lower intracellular pH [1, 7]. It may also inhibit fatty acid synthase I (FAS-I), although this remains a subject of scientific debate [1, 11].